MPNs

Novel Targets Outside of JAK Inhibition Inching into Myelofibrosis Treatment Landscape

August 31, 2020

Experts in myeloproliferative neoplasms find janus kinase inhibitors to be particularly important to the armamentarium for the treatment of myelofibrosis. With only 2 FDA-approved agents, fedratinib and ruxolitinib, and the inevitability that not all patients will derive benefit, and some will develop resistance, the option of moving beyond JAK inhibition is widely discussed.

Targeted Therapy Combinations With JAK inhibition Show Early Promise for Myelofibrosis

August 31, 2020

Patients with myelofibrosis have complicated pathology and multiple pathways, creating the opportunity to use multiple targeted agents for treatment, but also leading to greater potential for resistance to monotherapy, according to Lucia Masarova, MD.

Targeted Approach Considered for the Treatment of Accelerated/Blast Phase MPNs

August 31, 2020

Standard treatment for accelerated or blast phase myeloproliferative neoplasms consists of hypomethylating agents or intensive induction chemotherapy and transplant. However, newer studies have suggested that accelerated or blast phase MPNs, such as acute myeloid leukemia, can be treated with molecularly driven targeted therapies.

Determining Who Has “Early Myelofibrosis” Involves a Broad Look at Patient Factors

August 28, 2020

Patients considered to have early myelofibrosis are a heterogeneous group for whom disease risk, best treatment strategies, and the probability of mortality are best determined individually by looking at patient’s clinical characteristics and molecular markers together.